Please try another search
© Reuters. FILE PHOTO: Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo in this illustration photo
COPENHAGEN (Reuters) - A 60-year old Danish woman who died of a blood clot after receiving AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine had "highly unusual" symptoms, according to the Danish Medicines Agency.
The woman had a low number of blood platelets and clots in small and large vessels, as well as bleeding, it said.
A few similar cases were found in Norway and in the European Medicines Agency's (EMA) database of drug side effects, Danish Medicines Agency said.
"It was an unusual course of illness around the death that made the Danish Medicines Agency react," it said in a statement late on Sunday.
Norway said on Saturday that three people, all under the age of 50, who had received the AstraZeneca vaccine were being treated in hospital for bleeding, blood clots and a low count of blood platelets, which were labeled "unusual symptoms" by health authorities.
Denmark, Norway and Iceland said last week they would halt the introduction of the AstraZeneca vaccine.
European vaccination programmes have been upset in the last two weeks by reports that recipients of the AstraZeneca inoculation have suffered blood clots.
The European Medicines Agency has said there is no indication that the events were caused by the vaccination, a view that was echoed by the World Health Organization on Friday.
AstraZeneca Plc said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.
By David Shepardson WASHINGTON (Reuters) - U.S. traffic deaths jumped 10.5% in 2021 to 42,915 - the highest number killed on American roads in a single-year since 2005, regulators...
By David Stanway and Martin Quin Pollard SHANGHAI/BEIJING (Reuters) -Shanghai achieved its long-awaited milestone of three consecutive days with no new COVID-19 cases outside...
By Nancy Lapid (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.